Tag: Drug Discovery Award

Yan Niu | Pharmaceutical Science | Research Excellence Award

Published on by WSA Awards

Prof. Yan Niu | Pharmaceutical Science | Research Excellence Award

Peking University | China

Prof. Yan Niu is a medicinal chemist at Peking University whose research focuses on the discovery and optimization of biologically active small molecules, with special emphasis on hydrophobic tagging–based targeted protein degradation. She has contributed significant advances in amino-acid–derived hydrophobic tags capable of inducing selective POI degradation with mechanisms and pharmacological profiles distinct from PROTACs, expanding the chemical space available for next-generation degraders. With 47 Scopus-indexed publications, 549 citations, and an h-index of 14, her work bridges synthetic chemistry, chemical biology, and drug discovery. She has led competitive national projects, filed three patents, and collaborated internationally in Germany and Austria. Her research provides promising strategies for developing novel therapeutics and deepens mechanistic understanding of protein degradation pathways, contributing to innovation in medicinal chemistry and early-stage drug development.

Citation Metrics (Scopus)

500
450
300
150
0

Citations
549
Documents
47
h-index
14

Citations

Documents

h-index

Featured Publications

 

Jiunn-Liang Ko | Pharmaceutical Science | Research Excellence Award

Published on by WSA Awards

Prof. Jiunn-Liang Ko | Pharmaceutical Science | Research Excellence Award

Chung Shan Medical University | Taiwan

Dr. Jiunn-Liang Ko is a distinguished scholar in the fields of biochemistry, toxicology, and medical sciences, with a research career spanning more than three decades. He earned his Ph.D. in Biochemistry from the College of Medicine at National Taiwan University (1995), following a Master’s and Bachelor’s degree in Biology from Fu-Jen University. His academic and scientific journey reflects unwavering dedication to advancing biomedical research, particularly in molecular toxicology, environmental health, and translational medicine. Dr. Ko began his professional research career as a Postdoctoral Fellow at the Taiwan Agricultural Chemicals and Toxic Substances Research Institute, where he contributed to pioneering work in biopesticide safety and toxicological mechanisms. In 2003, he joined Chung-Shan Medical University, where he progressed from Professor in the Institute of Toxicology to Director of multiple strategic units, including the Research & Development Office, the Instrumental Center, and the Institute of Medical and Molecular Toxicology. His leadership has been instrumental in enhancing interdisciplinary research capacity, laboratory infrastructure, and academic excellence at the institution. Since 2011, Dr. Ko has served as Professor at the Institute of Medicine at Chung-Shan Medical University, continuing to lead high-impact research, mentor scholars, and foster international collaborations. His work encompasses molecular carcinogenesis, toxicogenomics, and the cellular responses to environmental hazards, positioning him as a key contributor to advancing understanding of public health risks and disease prevention. Over his career, he has authored numerous peer-reviewed publications, contributed to national and international projects, and collaborated across academia, healthcare, and applied science sectors. His research outputs are recognized for their scientific rigor and real-world relevance, influencing policy, clinical practice, and biosafety standards. Through his sustained academic leadership, scientific innovation, and commitment to education, Dr. Jiunn-Liang Ko continues to contribute significantly to global biomedical research and the advancement of public health.

Profiles: Scopus | ORCID | Google Scholar

Featured Publications

Yang, Y.-T., Hsu, C.-H., Wang, Y.-F., Chang, Y.-J., Yang, H.-J., Ko, J.-L., & Yang, K.-C. (2022). Worsening quality of life in young adult, highly educated, and married female patients with vitiligo: A hospital-based case control study in Taiwan. International Journal of Environmental Research and Public Health, 19(11), 6741.

Chang, J.-C., Chiou, J.-Y., Ko, J.-L., Huang, J.-Y., & Lue, K.-H. (2021). Early bronchiolitis contributes to preschool asthma. Children, 8(12), 1176.

Hsin, I.-L., Shen, H.-P., Chang, H.-Y., Ko, J.-L., & Wang, P.-H. (2021). Suppression of PI3K/Akt/mTOR/c-Myc/mtp53 positive feedback loop induces cell cycle arrest by dual PI3K/mTOR inhibitor PQR309 in endometrial cancer cell lines. Cells, 10(11), 2916.

Hsiao, Y.-P., Chen, H.-L., Tsai, J.-N., Lin, M.-Y., Liao, J.-W., Wei, M.-S., Ko, J.-L., & Ou, C.-C. (2021). Administration of Lactobacillus reuteri combined with Clostridium butyricum attenuates cisplatin-induced renal damage by gut microbiota reconstitution, increasing butyric acid production, and suppressing renal inflammation. Nutrients, 13(8), 2792.

Wu, S.-W., Ko, J.-L., Liu, B.-H., & Yu, F.-Y. (2020). A sensitive two-analyte immunochromatographic strip for simultaneously detecting aflatoxin M1 and chloramphenicol in milk. Toxins, 12(10), 637.

Omid Mehrpour | Pharmaceutical Science | Editorial Board Member

Published on by WSA Awards

Dr. Omid Mehrpour | Pharmaceutical Science | Editorial Board Member

Wayne State University | United States

Dr. Omid Mehrpour is a distinguished medical toxicologist, clinical data scientist, and physician whose work integrates toxicology, public health, and artificial intelligence to advance diagnostic accuracy and patient outcomes. With over two decades of academic, clinical, and research experience, he has become an internationally recognized expert in poisoning, substance use disorders, and AI-driven medical decision-making. Dr. Mehrpour has authored more than 200 peer-reviewed articles, ten book chapters, and a book translation, accumulating over 4,000 scientific citations. His publications and research outputs have significantly shaped clinical toxicology guidelines globally, particularly in areas related to opioids, heavy metals, aluminum phosphide, cannabinoids, and environmental toxicants. A pioneer in AI-based diagnostic innovation, Dr. Mehrpour developed machine learning–driven protocols for poison diagnosis, leading to two registered U.S. patents and additional patents in Iran for diagnostic software and toxicology devices. His work at the Rocky Mountain Poison & Drug Safety Center and collaborations with national databases such as NPDS and ToxIC contributed foundational methods for rapid identification and triage of poisoning cases. He has also led AI and clinical informatics initiatives at the University of Colorado Anschutz Medical Campus and founded AI and Health LLC to develop intelligent clinical tools that enhance diagnosis and care delivery. Throughout his career, Dr. Mehrpour has held leadership roles including Head of the Medical Toxicology and Drug Abuse Research Center and Director of the Poisoning Ward at Birjand University of Medical Sciences. He has supervised numerous graduate researchers and served on editorial boards of multiple international journals. His contributions have received global recognition, including placement among the top 2% of scientists worldwide, multiple “Top Reviewer” honors from Publons, and numerous national research awards. Dr. Mehrpour’s work continues to elevate the fields of toxicology, predictive modeling, and precision medicine, contributing impactful solutions that improve healthcare systems and advance patient safety worldwide.

Profiles: Scopus | ORCID

Featured Publications

1. Eizadi-Mood, N., Barzam, E., Pirali, Z., Feizi, A., Namvar, M., Abdi, E., Mirmoghtadaee, P., Mehrpour, O., & Meamar, R. (2025). Gender differences in opioid and stimulant poisoning in the central region of Iran: A cross-sectional study. Scientific Reports.

2. Amrollahi-Sharifabadi, M., Oladejo, T. O., Ibrahim, A. S., Shakoor, B., Mehrpour, O., Sadeghi-Hashjin, G., & Gonçalves, S. (2025). Melatonin’s paradox: From therapeutic benefits to toxicity warnings. Chemico-Biological Interactions, 111556.

3. Kooshki, A., Mansouri, B., Farmani, R., Amirabadizadeh, A., Mehrpour, O., Sanjari, M. J., & Nakhaee, S. (2024). Essential and toxic metal concentrations in biological samples of multiple sclerosis patients: A systematic review and meta-analysis. PLOS ONE, 19(12), e0313851.

4. Mehrpour, O., & Sadeghi, M. (2024). The occurrence of unusually cold weather could contribute to the incidence of carbon monoxide poisoning. Clinical and Experimental Emergency Medicine.

5. Nakhaee, S., Kooshki, A., Hormozi, A., Akbari, A., Mehrpour, O., & Farrokhfall, K. (2023). Cinnamon and cognitive function: A systematic review of preclinical and clinical studies. Nutritional Neuroscience.

Ashish Patel | Pharmaceutical Chemistry | Best Researcher Award

Published on by WSA Awards

Assoc. Prof. Dr. Ashish Patel | Pharmaceutical Chemistry | Best Researcher Award

Parul Institute of Pharmacy, Parul University, India

Dr. Ashish Patel is an Associate Professor at Parul Institute of Pharmacy, Parul University, Vadodara, Gujarat, with extensive expertise in Pharmaceutical Chemistry. He earned his M.Pharm degree from M.S. University of Baroda in 2010 and subsequently completed his Ph.D. at R.K. University in 2016, focusing on the design and development of bioactive compounds. Over the course of his academic career, Dr. Patel has guided more than 25 postgraduate students and 5 Ph.D. scholars, demonstrating his commitment to mentorship and fostering research excellence. His professional experience includes curriculum development, laboratory management, and active participation in national and international conferences, contributing to the academic community both as a researcher and educator. Dr. Patel’s research interests are broad and interdisciplinary, encompassing drug design, green synthesis, anti-cancer and anti-diabetic compounds, and computational chemistry, with particular emphasis on virtual screening and structure-activity relationship studies. His research skills include microwave-assisted synthesis, FT-IR spectroscopy, molecular docking, and computer-aided drug design, enabling him to bridge theoretical approaches with experimental validation. To date, he has published 83 research articles, accumulated 574 citations, and maintains an h-index of 15, reflecting the impact of his contributions to pharmaceutical sciences. Dr. Patel has been recognized for his excellence in teaching and research through multiple awards, including the Leadership Award in the Professor’s Training Program at Parul University, highlighting his dedication to professional development and leadership in academia. In conclusion, Dr. Ashish Patel exemplifies the integration of teaching, mentorship, and innovative research in pharmaceutical chemistry. His career reflects a sustained commitment to advancing scientific knowledge, nurturing future researchers, and contributing to the global understanding of drug discovery and development, establishing him as a distinguished figure in his field.

Profile: Scopus | ORCID | Google Scholar | Staff Page

Featured Publications

  1. Patel, A., Rajendran, M., Shah, A., Patel, H., Pakala, S. B., & Karyala, P. (2021). Virtual screening of curcumin and its analogs against the spike surface glycoprotein of SARS-CoV-2 and SARS-CoV. Journal of Biomolecular Structure and Dynamics, 1–9.

  2. Saralaya, M. G., Patel, P., Patel, A., Manish, Roy, & Samresh, Patel. (2010). Antidiarrheal activity of methanolic extract of Moringa oleifera Lam roots in experimental animal models. International Journal of Pharmaceutical Research, 2(2), 25–29.

  3. Patel, A., Patel, S., Mehta, M., Patel, Y., Patel, R., Shah, D., Patel, D., & Shah, U. (2022). A review on synthetic investigation for quinoline—Recent green approaches. Green Chemistry Letters and Reviews, 15(2), 337–372.

  4. Patel, A. D., Pasha, T. Y., Lunagariya, P., Shah, U., Bhambharoliya, T., … [additional authors]. (2020). A library of thiazolidin‐4‐one derivatives as protein tyrosine phosphatase 1B (PTP1B) inhibitors: An attempt to discover novel antidiabetic agents. ChemMedChem, 15(13), 1229–1242.

  5. Patel, P., Shah, D., Bambharoliya, T., Patel, V., Patel, M., Patel, D., Bhavsar, V., … [additional authors]. (2024). A review on the development of novel heterocycles as α-glucosidase inhibitors for the treatment of type-2 diabetes mellitus. Medicinal Chemistry, 20(5), 503–536.

Yves Patrick Ango | Chimie Pharmaceutique | Best Researcher Award

Published on by WSA Awards

Dr. Yves Patrick Ango | Chimie Pharmaceutique | Best Researcher Award

Faculty of Medicine and Biomedicals Sciences, the University of Yaoundé 1, Cameroon

Dr. Yves Patrick Ango is a distinguished Cameroonian researcher and Senior Lecturer at the Department of Pharmacotoxicology, Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, specializing in Natural Product Chemistry with a focus on isolating, characterizing, and testing bioactive compounds for anticancer and antimicrobial applications. He earned his Bachelor’s degree in Chemistry, followed by a Master’s and D.E.A. in Organic Chemistry at the University of Yaoundé I, and successfully completed his Doctorat/Ph.D. in Natural Product Chemistry with “Très Honorable” distinction. Throughout his career, Dr. Ango has combined academic excellence with international exposure, undertaking multiple research fellowships at the University of Botswana supported by IPICS, OPCW, DAAD, TWAS, and Humboldt networks, which enriched his expertise and fostered global collaborations in phytochemistry and pharmacology. His research portfolio includes 13 peer-reviewed publications in reputed journals such as Cancer Reports, Natural Product Research, Phytochemistry Letters, and Helvetica Chimica Acta, earning 202 citations and an h-index of 7, reflecting the impact of his scholarly contributions. His primary research interests revolve around discovering natural molecules with therapeutic potential, linking African traditional medicine to modern drug discovery, and addressing global health challenges such as cancer and drug resistance. Dr. Ango possesses strong research skills in natural product isolation, structural elucidation, biological activity testing, and collaborative scientific networking, alongside mentoring students and advancing pharmacotoxicology education in Cameroon. He has actively contributed to scientific development by participating in high-level international workshops and symposia, building knowledge-sharing platforms across Africa and Europe. His academic achievements and dedication to excellence have been recognized through prestigious international sponsorships and grants that reflect his research quality and leadership potential. With his passion for science, proven track record, and collaborative spirit, Dr. Yves Patrick Ango stands as a promising researcher whose contributions to natural product chemistry and biomedical innovation will continue to make a meaningful impact on global health research and capacity building.

Profile: Scopus | ORCID

Featured Publications

Akamse, M. A., Kamgo, V. D., Ango, P. Y.*, Djuidje Fotsing, M. C., Fomat, B. H. P., Mmutlane, E., Fotso, G. W., Kapche, D. W. F. G., Zingué, S., & Ndinteh, D. T. (2025). Arjunolic acid from Terminalia ivorensis A. Chev (Combretaceae) possesses anti-breast cancer effects in vitro and in vivo. Cancer Reports, 8(1), e70337, 1–14.

Choungo, V. N., Ango, P. Y.*, Nzepang, A., Fotso, G. W.**, Lenta, B. N., Sewald, N., & Kapche, D. W. F. G. (2025). Combretumlignan, a new cyclolignan and other constituents from Combretum zenkeri (Combretaceae). Heliyon.

Ango, P. Y.*, Kenembeni, M. K., Mapitse, R., Fotso, G. W., Garba, J. K., Mbazoa, C. D., Ndinteh, D. T., Kapche, D. W. F. G.**, & Wandji, J. (2025). The isolation, characterization and activity testing of two previously undescribed flavonoid glycosides and other constituents from the stem bark of Olax latifolia (Olacaceae). Natural Product Research.

Ango, P. Y.*, Ghoda, A. W., Abega, D. F., Mapitse, R., Kuete, V., Ngadjui, B. T., Fotso, G. W., & Kapche, D. W. F. G. (2024). Aframomumlabdane, a new bislabdane diterpenoid from Aframomum arundinaceum (Zingiberaceae). Natural Product Research.

Mogue, L. D. K., Ango, P. Y., Fotso, G. W., Mapitse, R., Kuete, V., Demirtas, I., Samuel, Y., & Ngadjui, B. T. (2019). Two new polyhydroxylated pentacyclic triterpenes with cytotoxic activities from Manilkara pelligriniana (Sapotaceae). Phytochemistry Letters, 31, 161–165.

Liang Zhou | Clinical Pharmacology | Best Researcher Award

Published on by WSA Awards

Ms. Liang Zhou | Clinical Pharmacology | Best Researcher Award

Shanghai Henlius Biotech Inc., China

Ms. Liang Zhou is a distinguished clinical pharmacology professional with extensive experience in oncology drug development, pharmacokinetics, and translational research. She earned her Master’s degree in Drug Metabolism and Pharmacokinetics from the China Pharmaceutical University in 2008, which laid the foundation for her successful career in pharmaceutical sciences. Over the years, she has held progressive positions in leading global and Chinese organizations, including Associate Senior Scientist at Wuxi Apptec, Demo Chemist at Thermo Fisher Shanghai, Associate Director of Clinical Pharmacology at Mosim, and currently serves as the Senior Director of Clinical Pharmacology at Shanghai Henlius Biotech, Inc. since 2021. In these roles, she has contributed to more than 11 significant clinical trial programs across China, Australia, Japan, Europe, and the United States, with a strong focus on first-in-human (FIH) trials, PK/PD analysis, and oncology indications such as breast cancer, lymphoma, AML, NSCLC, gastric and pancreatic cancers, among others. Her research interests center on oncology drug development, dose exploration studies, biomarker integration, and regulatory science to accelerate access to novel therapies. With 23 academic documents, 91 citations, and an h-index of 4, Ms. Zhou demonstrates measurable scholarly impact, supported by her memberships in professional societies such as the Chinese Society of Clinical Oncology (CSCO). She has also enhanced her expertise through specialized training in GCP compliance, oncology drug development, and advanced pharmacometrics including R-language applications. Her skills encompass pharmacokinetic modeling, clinical trial design, regulatory submission, and team leadership, which collectively position her as a key figure in clinical pharmacology. Recognized for her contributions to cancer research and drug development, she continues to build a strong professional profile with the potential for international recognition. In conclusion, Ms. Liang Zhou’s blend of academic excellence, clinical research leadership, and commitment to advancing oncology therapeutics makes her a deserving candidate for prestigious awards and a driving force in global biomedical innovation.

Profile: Scopus

Featured Publications

Li, X., Zhang, Y., Wang, J., Chen, H., Zhou, L., Liu, M., … [et al.]. (2023). HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: An open-label, dose-escalation, phase 1 trial.(5)

Asif Khaliq | Pharmaceutical Sciences | Best Researcher Award

Published on by WSA Awards

Dr. Asif Khaliq | Pharmaceutical Sciences | Best Researcher Award

Dr. Asif Khaliq is a distinguished clinical pharmacist and public health researcher with extensive experience across Pakistan and Australia. With over 15 years of cumulative expertise in pharmacy practice, healthcare management, and academic research, he has played pivotal roles in both hospital settings and global health research initiatives. Dr. Khaliq currently serves as a Clinical Pharmacist at Atherton Hospital, Queensland Health, where he contributes to medication reconciliation, patient consultation, and therapeutic drug monitoring. His broad qualifications in pharmacy, public health, and health management uniquely position him at the intersection of clinical service and evidence-based research. Notably, he has authored around 30 peer-reviewed journal articles and has presented his work at several international conferences. His commitment to improving patient care is reflected in his involvement in projects on antimicrobial stewardship, immunization safety, medication cost optimization, and community health surveillance. A registered pharmacist in both Australia and Pakistan, Dr. Khaliq continues to expand his professional credentials through ongoing training and professional development. His multidisciplinary knowledge and dedication to collaborative, data-driven healthcare improvement make him a leading candidate for honors in research and clinical excellence.

Professional Profile

Education

Dr. Asif Khaliq possesses a diverse and robust academic background that integrates pharmacy, health management, and public health. He earned his Doctor of Pharmacy (PharmD) from the University of Karachi in 2009, laying a solid foundation in pharmaceutical sciences. He later pursued an MBA in Health Management from the Institute of Business Management (IoBM), Karachi, in 2014, equipping him with managerial and strategic skills essential for healthcare administration. In 2017, he obtained a Master of Public Health (MPH) from Baqai Medical University, further expanding his expertise into population health, disease prevention, and health systems. Most recently, he completed a Ph.D. in Public Health at Queensland University of Technology (QUT), Australia, in 2023. His doctoral research focused on critical issues in public health, integrating practical clinical knowledge with research methodologies. In addition to these core degrees, Dr. Khaliq has cleared the Knowledge Assessment of Pharmaceutical Sciences (KAPS) by the Australian Pharmacy Council and has demonstrated English language proficiency through PTE Academic. His academic trajectory reflects a commitment to lifelong learning and interdisciplinary mastery, qualifying him to address complex healthcare challenges at both clinical and systemic levels.

Professional Experience

Dr. Khaliq’s professional journey spans multiple sectors, including hospital pharmacy, public health research, and academic instruction. Currently, he serves as a Clinical Pharmacist at Atherton Hospital under Queensland Health, where he provides vital services including medication review, drug interaction management, therapeutic optimization, and discharge planning. His responsibilities also involve daily clinical monitoring and interdisciplinary collaboration with physicians and nursing staff. Previously, he held pharmacist roles at Infinity Pharmacy Earlville Upper, Allora Pharmacy, and Boulder Pharmacy across Queensland, Australia. In these roles, he handled immunization services, controlled substance management, MedsChecks, and patient counseling. Notably, Dr. Khaliq served as a Research Coordinator at Aga Khan University Hospital, Pakistan, where he supervised international clinical trials and led efforts in typhoid outbreak investigations. He also worked in various pharmacist roles at Aga Khan University Hospital’s emergency and pediatrics departments, gaining critical experience in medication reconciliation, IV-to-oral drug conversions, and poison management. His early career included logistics and inventory roles with Médecins Sans Frontières, further enriching his understanding of pharmaceutical supply chains. This comprehensive experience makes Dr. Khaliq uniquely capable of blending clinical insights with research acumen and operational excellence.

Research Interests

Dr. Asif Khaliq’s research interests lie at the nexus of clinical pharmacy, public health, and healthcare systems management. He is particularly focused on areas such as antimicrobial stewardship, vaccine safety and immunogenicity, medication adherence, and cost-effective therapeutic strategies. During his Ph.D. studies at Queensland University of Technology, he explored healthcare outcomes linked to pharmacological practices and population-level health interventions. His work frequently integrates health surveillance, epidemiology, and evidence-based medicine to address real-world challenges in both hospital and community settings. He has led or contributed to major research projects including randomized controlled trials on antibiotic use in pediatric diarrhea and typhoid outbreak control. In recent roles, he has also investigated adverse events following immunization (AEFI), resistance patterns in Salmonella species, and systematic reviews on outbreak trends in developing regions. Dr. Khaliq is deeply committed to identifying research gaps in healthcare delivery and prescribing patterns, aiming to improve policy, patient outcomes, and clinical protocols. His interdisciplinary research interests reflect his training in pharmacy, health management, and public health, empowering him to make meaningful contributions to both academic literature and healthcare practice.

Research Skills

Dr. Khaliq possesses a broad and advanced set of research skills that enhance his ability to contribute to multidisciplinary studies and clinical investigations. He is highly proficient in clinical trial management, including participant recruitment, data collection, and adverse event reporting. His expertise extends to secondary data analysis, especially in reviewing hospital records, surveillance data, and immunization outcomes. He is experienced in systematic reviews and meta-analyses, utilizing medical databases and analytical frameworks to synthesize health evidence. Dr. Khaliq also brings strong capabilities in pharmacovigilance, therapeutic drug monitoring, and drug utilization evaluations. In the realm of academic publishing, he has served as a guest editor and peer reviewer, contributing to journal special issues and maintaining scientific rigor. He is adept at grant proposal development, contributing to multiple research applications during his tenure at academic and healthcare institutions. Moreover, his familiarity with health informatics tools—such as Micromedex, MedAdvisor, and clinical guidelines—enables him to integrate real-time data with clinical decision-making. His research skills are complemented by his teaching experience and mentorship, allowing him to train future researchers and practitioners in evidence-based methods.

Awards and Honors

Dr. Asif Khaliq has garnered recognition for his dedication to public health research and pharmaceutical practice through various academic and professional achievements. He was a selected speaker at notable international forums such as the IMPACT MAKER 2020 conference in Brisbane, where he presented novel research on coexisting forms of malnutrition. His earlier work on poisoning case management was also showcased at the 4th FMIC Conference in Kabul. At the 11th International Coalition Against Typhoid Conference in Hanoi, Vietnam, Dr. Khaliq presented two critical posters on typhoid drug resistance and outbreak investigation, underscoring his commitment to infectious disease research. He has published approximately 30 peer-reviewed papers, several of which have appeared in reputable international journals. While formal individual awards may not be listed, his multiple research leadership roles, international conference engagements, and responsibilities as a guest editor reflect his strong reputation in both academic and healthcare sectors. His continuous pursuit of professional certifications, including immunization and UTI management, also highlights a dedication to clinical excellence. These accomplishments collectively underscore his potential as an award-worthy contributor to global health and pharmacy practice.

Conclusion

In conclusion, Dr. Asif Khaliq exemplifies the ideal profile of a clinical researcher who bridges academic insight with frontline healthcare delivery. His academic credentials across pharmacy, health management, and public health are complemented by his extensive experience in clinical pharmacy settings in both Pakistan and Australia. Through his research on antibiotic use, immunization safety, and medication optimization, Dr. Khaliq addresses key healthcare challenges relevant to global and regional populations. He demonstrates not only technical knowledge but also leadership in research coordination, interdisciplinary collaboration, and scientific communication. His professional ethos is defined by evidence-based practice, patient-centered care, and continual improvement. As a registered pharmacist in two countries and an active participant in international academic dialogues, Dr. Khaliq is well-positioned to further influence policy, education, and clinical standards. His consistent pursuit of professional development, publication, and mentorship reflects a commitment to excellence that aligns with the objectives of the Best Researcher Award. Recognizing his contributions would not only honor individual achievement but also highlight the critical role of pharmacist-researchers in shaping modern healthcare systems.

Publications Top Notes

1. Mission of Polio Eradication in Pakistan – A Review on Challenges and Future Recommendations

  • Year: 2025

  • Source: New Microbes and New Infections (Open Access)

2. Adherence to Complementary Feeding Indicators and Their Associations with Coexisting Forms of Malnutrition in Children Aged Between 6 to 23.9 Months of Age

  • Year: 2023

  • Source: Journal of Public Health

 

Yulin Mo | Pharmaceutical Science | Best Researcher Award

Published on by WSA Awards

Dr. Yulin Mo | Pharmaceutical Science | Best Researcher Award

Shanghai University, China

Mo Yulin is an accomplished researcher and medical professional specializing in pharmacology and traditional Chinese medicine. Born in 1986 in Hezhou, Guangxi, China, he currently serves as a physician at Nanning Hospital of Traditional Chinese Medicine. With over a decade of clinical and research experience, Mo combines medical practice with scientific inquiry, focusing on the mechanistic basis of bone diseases such as glucocorticoid-induced osteoporosis (GIO). He obtained his Master of Medical Science degree in Pharmacology from Guangdong Medical University, where he cultivated a strong foundation in experimental pharmacology, molecular techniques, and data analysis. His academic journey began at Youjiang Medical University for Nationalities, where he earned his Bachelor’s degree in Clinical Medicine. Mo Yulin has actively contributed to several nationally funded research projects and has co-authored high-impact journal articles. His work focuses on the intersection of Traditional Chinese Medicine and modern pharmacological research, particularly targeting bone-related diseases. With a sound understanding of laboratory protocols, animal models, and statistical software, he continues to contribute to both clinical and academic advancements. Mo’s research is well-recognized in peer-reviewed journals and by national scientific foundations, reinforcing his potential as a leading figure in integrative medical research.

Professional Profile

Education

Mo Yulin’s educational background is rooted in a solid blend of clinical and pharmacological sciences. He began his academic journey at Zhaoping County Middle School, completing his secondary education in 2004. He then enrolled at Youjiang Medical University for Nationalities in September 2005, where he pursued a Bachelor’s degree in Clinical Medicine and graduated in June 2010. His interest in the theoretical underpinnings of medicine and drug mechanisms led him to pursue postgraduate studies in Pharmacology. In September 2016, he was admitted to Guangdong Medical University, a recognized institution in medical sciences, where he undertook a full-time Master’s program in Medical Science with a concentration in pharmacology. He completed this program in June 2019. His master’s thesis, titled “Exploring the pathogenesis of GIO and the intervention effect of Danshensu based on TXNIP mediated mitochondrial oxidative phosphorylation,” demonstrated a deep integration of molecular biology, pharmacology, and traditional Chinese medicine. His academic record is also supplemented by participation in various specialized training programs and international summer courses, including workshops on stem cell biology and network pharmacology. This extensive and interdisciplinary academic training has equipped him with a broad understanding of clinical medicine, experimental design, and the pharmacological sciences.

Professional Experience

Mo Yulin has built an impressive career that bridges clinical practice and biomedical research. His professional journey began in June 2010 when he joined the Nanning Hospital of Traditional Chinese Medicine as a medium physician in the Internal Medicine and Physical Examination departments. Over six years in this role, he developed a strong clinical foundation and a growing interest in disease mechanisms and pharmacological interventions. After obtaining his Master’s degree, he returned to the same hospital in June 2019, this time focusing on a broader medical department, where he continues to practice medicine. During his tenure, Mo has maintained a dual focus on patient care and experimental research, allowing him to apply his laboratory insights to real-world medical challenges. He has collaborated with senior professionals and contributed to national-level research, while also mentoring younger colleagues in clinical routines and laboratory practices. His unique ability to translate bench-side findings to bedside interventions highlights his effectiveness as both a clinician and a researcher. With over a decade of continuous professional involvement in the medical field, Mo has shown commendable commitment, especially in the integration of traditional Chinese therapies with modern biomedical strategies.

Research Interest

Mo Yulin’s research interests lie primarily at the intersection of traditional Chinese medicine and modern pharmacological science, with a particular emphasis on bone-related disorders and oxidative stress mechanisms. He is especially passionate about understanding and treating glucocorticoid-induced osteoporosis (GIO) using molecular and cellular approaches. His master’s thesis explored the TXNIP-mediated mitochondrial oxidative phosphorylation pathway as a contributor to bone loss, representing a critical nexus of energy metabolism and bone pathology. Mo is also interested in the pharmacological potential of natural Chinese medicine, including monomer compounds and complex formulations, to treat chronic diseases such as osteoporosis, vascular diseases, and diabetes. Another area of interest includes modeling disease conditions in animals—he has mastered several techniques to establish experimental models, including ovariectomized rats and glucocorticoid-induced fracture models. Additionally, Mo is fascinated by the application of bioinformatics and network pharmacology to identify active compounds in traditional medicines and link them to molecular targets. His broader academic pursuit is to modernize traditional therapies by uncovering their mechanisms of action at the cellular and genetic level. By combining ancient medical wisdom with cutting-edge scientific techniques, he aims to contribute to integrative medicine and develop more effective, evidence-based therapeutic strategies.

Research Skills

Mo Yulin possesses a comprehensive skill set spanning molecular biology, pharmacological modeling, histology, and data analytics. He is highly proficient in conducting experiments involving animal models, particularly in the induction of osteoporosis and bone fractures in rodents. His technical skills include the extraction and culturing of bone marrow mesenchymal stem cells, human osteosarcoma cell lines, and various molecular biology assays like Western blotting, RT-qPCR, MTT assays, plasmid transfection, and siRNA interference. He is also skilled in bone histomorphometry, micro-CT analysis, and both decalcified paraffin and non-decalcified plastic embedding techniques. Mo is adept at performing immunohistochemistry and various types of staining for microscopic analysis. In addition to wet-lab skills, he is well-versed in statistical analysis and scientific computing using software such as SPSS, GraphPad Prism, and ImageJ. His ability to combine laboratory expertise with data interpretation and literature synthesis makes him a competent and independent researcher. Furthermore, he is capable of integrating traditional Chinese medicine theory with modern biochemical analysis, allowing for novel insights into drug mechanisms. These versatile research skills equip him to work on multidisciplinary projects in both academic and clinical research settings.

Awards and Honors

Throughout his academic and professional career, Mo Yulin has been recognized for his analytical acumen and research capability. During his undergraduate studies, he participated in the National College Students Mathematical Modeling Competitions, where he won the second prize in 2006 (Guangxi B group) and the third prize in 2007 (Guangxi group A). These early accomplishments reflected his strong foundation in analytical thinking and a keen interest in applying quantitative methods to solve biomedical problems. Later, his master’s thesis was selected for review by the Academic Degrees Committee of Guangdong Province, a sign of academic excellence. In addition, Mo has participated in several prestigious training programs and conferences, such as the Croucher Foundation’s summer course on Stem Cell Biology and Regenerative Medicine at the Chinese University of Hong Kong. He was also selected for training in Network Pharmacology Technology of Traditional Chinese Medicine and participated in the 9th International Academic Conference on Osteoporosis and Bone Mineral Salt Diseases, contributing to his professional growth and global exposure. These accolades, combined with his inclusion as a project participant in national-level funded research, highlight his growing stature as a serious and capable biomedical researcher.

Conclusion

In conclusion, Mo Yulin is a highly capable and dedicated researcher with a unique profile that bridges clinical medicine and pharmacological science, especially within the framework of Traditional Chinese Medicine. His academic achievements, research capabilities, and publication record affirm his suitability for a distinguished research career. He has already contributed valuable insights into the understanding and treatment of bone-related disorders and oxidative stress, demonstrated by peer-reviewed publications in high-impact journals and successful participation in national research projects. Mo’s well-rounded expertise, from cell culture and animal modeling to statistical data analysis and Chinese medicinal compound evaluation, gives him a holistic view of disease pathology and therapeutic mechanisms. Although a Ph.D. degree and more international collaborations could further enhance his research impact, his current contributions and potential for future work are substantial. Mo Yulin is not only a skilled physician but also a thoughtful researcher whose work continues to bridge gaps between traditional knowledge and modern science. Based on his achievements and potential, he stands out as a strong candidate for the Best Researcher Award.

Publications top Notes

  1. TXNIP contributes to bone loss via promoting the mitochondrial oxidative phosphorylation during glucocorticoid-induced osteoporosis
    Authors: Yulin Mo, Wenxiu Lai, Ying Zhong, Zhuoqing Hu, Meigui You, Minqun Du, Pan Wang, Xinyou Wu, Cailing Chen, Huanmin He, Zhimin Gao, Yaping Xu, Dongtao Wang, Liao Cui, Yajun Yang
    Year: 2021
    Journal: Life Sciences 266 (2021): 118938
  2. Tanshinol alleviates microcirculation disturbance and impaired bone formation by attenuating TXNIP signaling in GIO rats
    Authors: Wenxiu Lai, Yulin Mo, Dongtao Wang, Ying Zhong, Lujiao Lu, Jiajia Wang, Liao Cui, Yanzhi Liu, Yajun Yang
    Year: 2021
    Journal: Frontiers in Pharmacology, 12: 722175
  3. The mechanism of TXNIP-mediated oxidative stress in the disease
    Authors: Mo Yulin, Yang Yajun, Cui Liao
    Year: 2018

 

 

Gollapalle Lakshminarayanshastry Viswanatha | Pharmacology | Best Researcher Award

Published on by WSA Awards

Dr. Gollapalle Lakshminarayanshastry Viswanatha | Pharmacology | Best Researcher Award

Manipal College of Pharmaceutical Sciences, MAHE, Manipal, India

Dr. Gollapalle L. Viswanatha is a distinguished pharmacologist and toxicologist with over 17 years of expertise in pharmaceutical R&D, regulatory toxicology, and preclinical research. Currently serving as a Manager at ClinChoice Pvt. Ltd., Bengaluru, he has held pivotal roles in organizations like IQVIA, The Himalaya Drug Company, and Connexios Life Sciences. A prolific academic and industry contributor, Dr. Viswanatha has authored over 100 peer-reviewed articles and delivered more than 20 expert talks in global forums. As a DABT-certified and European Registered Toxicologist (ERT), his work bridges cutting-edge science with regulatory excellence. He also serves as adjunct faculty at Manipal College of Pharmaceutical Sciences, mentoring postgraduate students and contributing to academic research. His pioneering efforts in herbal drug evaluation, regulatory documentation, and systematic reviews make him a leading voice in toxicology and pharmacology. With several novel animal models to his credit, he actively influences drug discovery and translational medicine.

Professional Profile

Educational 

Dr. Viswanatha holds a PhD in Pharmaceutical Sciences (2019) from JNTU Anantapur, with a dissertation focused on indigenous medicinal plants against stroke and epilepsy. He is board-certified by the American Board of Toxicology (DABT, 2023) and recognized as a European Registered Toxicologist (ERT, 2022). He completed a PG Diploma in Statistical Quality Control and earned a Six Sigma Green Belt from the Indian Statistical Institute (ISI), Bengaluru in 2017, both with Grade ‘A’. He holds an M. Pharm in Pharmacology (2008) from RGUHS, Bengaluru, graduating with 77% and was honored as the Best Outgoing Student. Additionally, he is a GATE and GPAT qualifier. His academic foundation is marked by a multidisciplinary understanding of pharmacology, quality systems, and toxicology. Throughout his academic journey, he has demonstrated a commitment to both practical research and methodological rigor, blending statistical competence with clinical relevance in drug discovery and safety sciences.

Professional Experience

Dr. Viswanatha has a robust professional background spanning regulatory toxicology, preclinical pharmacology, and data surveillance. Currently, he leads the toxicology division at ClinChoice Pvt. Ltd. (2021–present), overseeing cosmetic ingredient safety, CTD preparation, biocompatibility risk assessments, and toxicological risk evaluations. He formerly worked at IQVIA India Pvt. Ltd. (2014–2021) as a Senior Medical Data Reviewer, specializing in clinical trial surveillance and protocol compliance for myocardial infarction studies. Prior to that, he served as a Research Associate at The Himalaya Drug Company (2010–2014), standardizing herbal drug models, and as a Scientist at Connexios Life Sciences (2008–2010), handling PK, safety pharmacology, and toxicological assessments of NCEs. His interdisciplinary approach combines GLP compliance, regulatory documentation, safety evaluations, and project leadership. With broad expertise across pharmaceuticals, nutraceuticals, and cosmetics, he has contributed to product development from discovery to regulatory submission while mentoring cross-functional teams and managing end-to-end project execution.

Awards and Honors 

Dr. Viswanatha has received numerous accolades throughout his academic and professional journey. He was honored with the prestigious Joe-Mae International Young Scientist Award by the AMS Society in Hong Kong (2016) and was a nominee for the Dr. Achari Award at IPSCON 2012 for his work on a novel pharyngitis animal model. He earned the title of Best Outgoing Student during his M. Pharm (2006–2008) and successfully qualified in GATE 2007, GPAT 2010 & 2011. His innovative contributions include the development of novel animal models for non-infectious pharyngitis and hemorrhoids. He has been invited for over 10 expert talks, delivered 5 hands-on workshops, and reviewed articles for over 35 high-impact journals, reflecting his standing as a respected thought leader. These honors underscore his commitment to translational pharmacology, scientific innovation, and academic mentorship, bridging traditional medicine with modern pharmacological practices.

Research Interests 

Dr. Viswanatha’s research interests span preclinical pharmacology, regulatory toxicology, herbal medicine, and evidence-based drug evaluation. His work focuses on stroke, epilepsy, neurodegeneration, nephroprotection, pharyngitis, and gastrointestinal and cardiovascular pharmacology, often using rodent models. He has a strong inclination toward toxicological risk assessment (TRA), biocompatibility studies, and regulatory documentation for pharmaceuticals and cosmetics. His current pursuits involve systematic reviews and meta-analyses on both clinical and preclinical data, particularly emphasizing GABAergic modulation, anti-inflammatory agents, and flavonoids like naringin. He also contributes to safety pharmacology and real-world evidence generation. Beyond therapeutic investigations, he’s deeply involved in OECD-compliant toxicology, SCCS cosmetic safety dossiers, and ISO 10993-based device safety evaluations. His dual strength in bench science and regulatory frameworks makes his research both impactful and implementation-ready, aligning traditional pharmacological principles with global safety standards.

Research Skills

Dr. Viswanatha possesses advanced skills in in vivo and in vitro pharmacological/toxicological experimentation, including GLP-compliant animal models using rats, mice, rabbits, and guinea pigs. He is proficient in conducting acute, repeated dose, and genotoxicity studies, and safety pharmacology evaluations per ICH guidelines. He excels in meta-analysis and systematic reviews using RevMan, RoB-2, G-Power, and Newcastle-Ottawa scales, alongside regulatory documentation (CTD modules 2.4 & 2.6, CPSR, ADE/PDE/OEL assessments). He has expertise in SCCS guidelines, QSAR & AOT software tools, and data analysis using GraphPad Prism, SPSS, and Minitab. He’s also skilled in toxicological literature mining using PubMed, ECHA, PubChem, and other databases. A Six Sigma Green Belt and SQC professional, his approach blends quality systems with analytical rigor. His research strengths lie in project management, protocol development, real-world evidence integration, and regulatory toxicology strategy, making him an asset across life sciences domains.

Conclusion

Dr. Viswanatha exemplifies a rare blend of rigorous experimental pharmacology and robust regulatory toxicology. His multidisciplinary education and certifications, from PhD to international toxicology credentials, underpin his leadership in both academic and industry domains. With a strong track record in innovative animal model development, systematic reviews, and regulatory documentation, he drives preclinical-to-clinical translation effectively. His prolific publication record, awards, and advisory roles highlight a distinguished career that continues to influence global life sciences.

 Publication Top Notes

  • 🧠 Clinical study on cisplatin‑induced nephrotoxicity in humans – PA Arunkumar et al. (2012)

  • 🌿 Ethnopharmacology of Lepidium sativum Linn: A review – D Manohar et al. (2012)

  • 🍃 Antioxidant & anti-inflammatory activity of Mangifera indica leaf extracts – CG Mohan et al. (2013)

  • 🍊 Naringin’s neuroprotective neurobehavioral review/meta-analysis – GL Viswanatha et al. (2017)

  • 🍎 Isolation of antidiabetic principle from Punica granatum rinds – V Jain et al. (2012)

  • 🌳 POG‑glucose inhibits 11β‑HSD‑1 & ameliorates diet-induced diabetes – CG Mohan et al. (2013)

  • 🍋 Lemongrass oil for dexamethasone-induced hyperlipidemia – VRS Kumar et al. (2011)

  • 💊 Hepatoprotective activity of Hepax polyherbal formulation – VC Devaraj et al. (2011)

  • 🌿 Antioxidant & antimutagenic activities of Terminalia arjuna bark – GL Viswanatha et al. (2013)

  • 🩸 Rat model of hemorrhoids: anti‑hemorrhoidal study – M Azeemuddin et al. (2014)

  • 💧 LC‑MS/MS quantification of flavonoids in Moringa & Raphinus – VC Devaraj et al. (2011)

  • 🧠 Animal models of chemotherapy‑induced cognitive decline – J John et al. (2021)

  • 💡 Bacopa monnieri + rivastigmine memory reversal in rats – AHM Thippeswamy et al. (2016)

  • 🍊 Hesperidin’s neuroprotective & mitochondrial benefits – GL Viswanatha et al. (2012)

  • ⚡ Anti‑epileptic activity of Punica granatum leaf extracts – GL Viswanatha et al. (2016)

  • 🌲 Anxiolytic & anticonvulsant activity of Cedrus deodara – GL Viswanatha et al. (2009)

  • 🧠 POG‑glucose alleviates ischemia/reperfusion brain injury – GL Viswanatha et al. (2013)

  • 🧪 Anti‑ulcer effect of Raphinus sativus leaves – VC Devaraj et al. (2011)

  • 🌱 Gymnema sylvestre extract improves glucose uptake – PM Kumar et al. (2016)

  • 🍇 Phytochemical standardization of Punica granatum – V Jain et al. (2011)

  • 🌸 Anti‑fertility activity of Tabernaemontana divaricata flowers – MA Mukhram et al. (2012)

  • 🧊 Anti‑urolithiatic effect of Cedrus deodara extract – N Krishnadas et al. (2010)

  • 💩 Antidiarrheal activity of Thespesia populnea bark fractions – GL Viswanatha et al. (2011)

  • 🦴 Anti‑osteoporotic effect of herbal formula NR/CAL/06 – P Srikanta et al. (2011)

  • 🌿 Antidiarrheal activity of Lepidium sativum seed extract – D Manohar et al. (2011)

  • 🧠 Acteoside from Colebrookea – anti‑epileptic effects – GL Viswanatha et al. (2016)

  • 💊 Thienotriazines: synthesis & antihistaminic activity – GL Viswanatha et al. (2012)

  • 🧠 Punica granatum extract protects against I/R brain injury – GL Viswanatha et al. (2014)

  • 🌱 Colebrookea oppositifolia root for stroke – cerebroprotective effect – GL Viswanatha et al. (2019)

  • 💥 Anticonvulsant activity of POG‑glucose from Mangifera indica – GL Viswanatha et al. (2018)

  • 💊 Mechanisms of biochanin‑A: a pharmacological review – PV Anuranjana et al. (2010)

  • 🧬 Diabetic wound healing: update – R Keni et al. (2012)

  • 🛡️ Cardioprotective preclinical systematic review on naringin – GL Viswanatha et al. (2023)

  • 🌿 Ethnopharmacology of Lepidium sativum Linn. review – M Divanji et al. (2022)

  • 🧠 Erythrina variegata bark extract: anxiolytic & anticonvulsant – G Pitchaiah et al. (2023)

 

Cem Calışkan | Pharmaceutical Science | Best Researcher Award

Published on by WSA Awards

Dr. Cem Calışkan | Pharmaceutical Science | Best Researcher Award

R&D Manager from World Medicine, Turkey

Dr. Cem Çalışkan is an accomplished R&D Manager and pharmaceutical researcher with a distinguished background in analytical chemistry, method development, and regulatory compliance. His professional journey is marked by extensive contributions to the pharmaceutical industry, particularly in analytical method validation, formulation development, and laboratory accreditation processes. With over a decade of progressive experience, Dr. Çalışkan has held key roles at leading pharmaceutical organizations including World Medicine and Neutec İlaç, consistently driving innovation and excellence in pharmaceutical R&D. His academic background features a Ph.D. in Analytical Chemistry from Yıldız Technical University, complemented by a Master’s degree in Organic Chemistry and ongoing Executive MBA studies at Istanbul University, reflecting a multidisciplinary approach to science and leadership. Dr. Çalışkan’s portfolio includes several peer-reviewed publications in top scientific journals, where he explores themes such as nitrosamine detection, impurity profiling, stability-indicating methods, and in-vitro drug release. His research not only addresses critical analytical challenges but also aligns with global regulatory standards. With a passion for mentoring, scientific rigor, and innovation, Dr. Çalışkan exemplifies the integration of academic excellence and industrial impact, making him a strong candidate for scientific recognition at the international level.

Professional Profile

Education

Dr. Cem Çalışkan has a comprehensive and interdisciplinary educational background that has shaped his expertise in analytical and organic chemistry as well as pharmaceutical development. He earned his Doctor of Philosophy (Ph.D.) in Analytical Chemistry from Yıldız Technical University between 2018 and 2022, where he focused on advanced analytical techniques and pharmaceutical applications. His doctoral work provided the foundation for several high-impact scientific publications and patents in method validation and impurity analysis. To complement his scientific expertise with managerial insight, Dr. Çalışkan is currently pursuing an Executive MBA at Istanbul University (2024–present), focusing on strategic business management and leadership in the pharmaceutical industry. His academic journey also includes a Master of Science in Organic Chemistry from Sakarya University (2014–2016), where he deepened his understanding of chemical reactions, drug formulation, and molecular mechanisms. He holds a Bachelor of Science in Chemistry from Uludağ University (2003–2009), which laid the initial groundwork for his professional path in R&D. This strong academic progression, spanning both the sciences and management, enables Dr. Çalışkan to bridge the gap between innovative research and strategic decision-making in the pharmaceutical sector.

Professional Experience

Dr. Cem Çalışkan’s professional experience reflects a sustained commitment to innovation and quality in pharmaceutical research and development. Since 2020, he has been serving as the R&D Manager at World Medicine, where he leads cross-functional teams in analytical development, method validation, and compliance with international regulatory standards. In this role, he initiated the patented WMINOLAB analytical service model, exemplifying his vision for high-quality, independent R&D frameworks. Prior to this, from February to August 2020, he held the position of R&D Analytical Development Chief at the same organization, coordinating sustainable business process models, documentation systems, and team development initiatives. Between 2013 and 2020, Dr. Çalışkan worked as an R&D Responsible Specialist, playing a critical role in analytical method development, stability testing, and responding to regulatory queries from global authorities. Earlier in his career, he served as a Process Development Analyst at Neutec İlaç (2011–2013), where he conducted formulation trials, transfer validations, and documentation for CTD Module III. These roles have not only honed his technical capabilities but also highlighted his strategic thinking, regulatory insight, and project management skills in both domestic and international pharmaceutical landscapes.

Research Interests

Dr. Cem Çalışkan’s research interests center on pharmaceutical analytical chemistry, with a special focus on developing novel methods for impurity profiling, drug stability studies, and nitrosamine risk assessment. He is deeply engaged in creating robust and regulatory-compliant analytical methodologies using cutting-edge instruments such as LC-MS/MS, RP-HPLC, and FTIR spectroscopy. His scientific inquiries aim to improve the accuracy, reproducibility, and efficiency of pharmaceutical testing methods, ensuring safer and more effective drug formulations. A key area of his work involves validating stability-indicating methods for various drug compounds, exploring the physicochemical behavior of active pharmaceutical ingredients (APIs) and excipients under stress conditions. He is also involved in studies on in-vitro drug release, polymer membrane permeability, and analytical compatibility of formulation components. In recent years, Dr. Çalışkan has broadened his scope to include the assessment of genotoxic impurities and packaging-related contaminant analysis, which are critical in modern pharmaceutical safety regulations. His interest in bridging laboratory innovation with regulatory frameworks is reflected in his leadership of accredited research labs and method development teams. This intersection of research excellence and industry relevance defines his contribution to the evolving landscape of pharmaceutical sciences.

Research Skills

Dr. Cem Çalışkan possesses a broad and advanced skill set in pharmaceutical R&D, particularly in the analytical domain. His technical proficiency includes the use of LC-MS/MS, RP-HPLC, FTIR, UV-Vis spectroscopy, and gravimetric analysis for method development, validation, and impurity determination. He is well-versed in Good Laboratory Practice (GLP) and has led numerous method validation studies, including for high-risk pharmaceutical substances like nitrosamines and complex impurities. His skills extend to process optimization, formulation compatibility testing, and the analytical transfer of drug products across laboratories and regulatory environments. Dr. Çalışkan also excels in scientific documentation, protocol writing, and preparation of CTD Module III files for regulatory submission. Beyond technical expertise, he has notable experience in project management, cross-departmental coordination, and team training, equipping him to lead dynamic research teams. His communication skills support effective regulatory correspondence with ministries and international partners, while his analytical thinking aids in critical decision-making across all stages of pharmaceutical development. Combined, these research skills make him not only a technically sound researcher but also an effective scientific leader.

Awards and Honors

While specific awards and honors are not listed in his current profile, Dr. Cem Çalışkan’s career accomplishments reflect a reputation for research excellence and industrial innovation. His leadership in the development and implementation of WMINOLAB, a patented analytical service platform within World Medicine, stands as a testament to his ability to deliver novel, scalable solutions to industry-wide challenges. His publications in reputable journals such as the Journal of Pharmaceutical Sciences, European Journal of Mass Spectrometry, and Journal of AOAC International showcase his academic influence and contributions to pharmaceutical quality control and safety. Additionally, Dr. Çalışkan has played a crucial role in securing and maintaining laboratory accreditations, further evidencing his standing in the professional R&D community. With continued recognition through publications, cross-functional leadership roles, and innovation in analytical techniques, it is evident that he is well-positioned for formal accolades in both industrial and academic circles. Nomination for a Best Researcher Award would be a fitting acknowledgment of his significant impact on pharmaceutical research and method validation at both national and international levels.

Conclusion

Dr. Cem Çalışkan represents a compelling candidate for the Best Researcher Award, bringing together scientific rigor, innovative thinking, and impactful leadership in the pharmaceutical sector. His multi-tiered education, from chemistry through analytical science to business management, empowers him to operate effectively at the intersection of research, industry, and regulation. His extensive experience with analytical method development, impurity profiling, and compliance documentation, along with his proactive approach to laboratory innovation, positions him as a distinguished researcher. His publication record reinforces his scientific credibility, while his managerial roles highlight his ability to lead R&D initiatives with strategic foresight. What sets Dr. Çalışkan apart is not only his technical excellence but also his drive to elevate pharmaceutical research standards in Turkey and beyond. As the industry faces increasing regulatory scrutiny and demands for innovation, his skill set is more relevant than ever. Recognizing his achievements through a Best Researcher Award would honor a career dedicated to advancing analytical science and fostering pharmaceutical innovation, while inspiring emerging researchers to pursue excellence in both academia and industry.

Publications Top Notes

1. Comparison of permeability of topical Cream drug through polymer synthetic membranes of different structures using Franz Cell diffusion test

  • Authors: Cihan Torlak, Müge Güleli, Şevki Kızılok, Remziye Azra Kartop, et al.

  • Year: 2024

  • Journal: Journal of Dispersion Science and Technology

2. Evaluation of a Novel LC‑MS/MS Based Analytical Method for the Risk Assessment of Nitrosamines in Pharmaceutical Products and Packaging Materials

  • Authors: Remziye Azra Kartop, Cihan Torlak, et al. (study led by Kartop and colleagues)

  • Year: 2024

  • Journal: Journal of Pharmaceutical Sciences

3. Simultaneous quantification of tiotropium bromide impurities G + H in capsule formulation by LC‑MS/MS

  • Authors: Not specified in preview

  • Year: 2023

  • Journal: European Journal of Mass Spectrometry